PHARMACY

Take Care adds four new vaccines to its program

BY Antoinette Alexander

CONSHOHOCKEN, Pa. Take Care Health Systems, which is owned by Walgreens, has expanded its vaccine program with four new vaccines.

The new vaccination suite includes varicella (chickenpox); measles, mumps and rubella (MMR); pneumococcal (PPV); and human pappilomavirus (HPV).

These vaccinations—in addition to hepatitis B, menactra (meningitis), shingles, tetanus, diphtheria, pertussis (Tdap) and tetanus booster (Td)—are now available at all 223 Take Care clinics within Walgreens.

Flu shots will also be available from Oct. 1 through early 2009.

“Vaccinations are the cornerstone of disease prevention and health promotion,” stated Sandy Ryan, chief nurse practitioner officer at Take Care Health Systems. “Routine immunizations are critical for both children and adults. Adults should ensure they are up to date on recommended vaccines to prevent against common, yet serious, diseases.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Glue-like bacterial sugar could lead to vaccine

BY Alaric DeArment

LONDON A study has found that when manipulated with chemicals, a sugar that drug-resistant bacteria secrete triggered an immune response in animals.

The study, presented last week at the Dublin, Ireland, meeting of the Society for General Microbiology used a glue-like sugar that bacteria produce to protect themselves from antibiotics called PNAG.

PNAG alone does not produce an immune response in most people and animals, but the researchers, from the Harvard Medical School, hope that formulations of it do.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA announces likely delay on Novo Nordisk diabetes drug

BY Alaric DeArment

WASHINGTON The Food and Drug Administration has announced that it will be unable to meet the user fee deadline for a timely approval of Novo Nordisk’s drug liragludite.

The FDA will not be able to make an approvability decision until March 23 for the drug, a treatment for Type 2 diabetes. Novo Nordisk had submitted an approval application for the drug on May 23.

The standard review period for FDA action on approval applications is 10 months. Because the agency’s advisory committee meeting will take place shortly before March 23, however, its decision will probably be delayed by a further two months, the company said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?